Table 1 Demographic and clinical data of the study group
| Â | Secondary hyperparathyroidism (N = 61) | Reference value |
|---|---|---|
Female/male | 38/23 | Â |
Age (years) | 57.11 ± 13.12 | |
Hemodialysis/peritoneal dialysis | 57/4 | |
Calcium (mg/dL) | 10.10 ± 0.80 | 8.4–10.6 |
Phosphate (mg/dL) | 5.68 ± 1.56 | 2.1–4.7 |
Calcium x Phosphate (mg2/dL2) | 57.51 ± 12.01 | |
Alkaline phosphatase (U/L) | 219.44 ± 194.81 | 42–128 |
Intact parathyroid hormone (pg/mL) | 1194.50 ± 389.69 | 8.0–76.0 |
DKK1(pmol/L) | 41.38 ± 21.59 | |
Sclerostin (pmol/L) | 7.76 ± 4.26 | |
Body weight (kg) | 58.47 ± 10.42 | |
Dialysis duration (months) | 93.37 (62.89,130.37) | |
25(OH) Vitamin D (ng/mL) | 27.94±12.0 | >30 |
Albumin (g/dL) | 3.85 ± 0.41 | 3.7-5.3 |
Total cholesterol (mg/dL) | 179.07 ± 41.22 | 125-240 |
Triglyceride (mg/dL) | 167.49± 151.33 | 20-200 |
BMD femoral neck (gm/cm2) | 0.57 ± 0.15 | |
BMD lumbar spine (gm/cm2) | 0.84 ± 0.18 | |
T-score of femoral neck | -2.83± 1.16 | |
Z-score of femoral neck | -1.43± 0.18 | |
Systolic blood pressure | 143.75± 21.55 | |
Diastolic blood pressure | 80.39±10.65 | |
Coronary artery (Agatston unit) | 1570 (248.5,3701) | |
Coronary artery (volume score) | 1322 (226.5,3252.5) | |
Aortic valve calcification | 42.6% | |
Mitral valve calcification | 47.5% | |
Intravenous pulse calcitriol | 16.4% | |
Diabetes mellitus | 16.4% | |
Hypertension | 65.6% | |
Smoking | 1.6% | |
Anti-hypertension drugs | 65.6% | |
Lipid lower agents | 9.8% |